TB
Theravance Biopharma Inc
TBPH · NASDAQ
$17.02 -0.06% (-$0.01)
1M +0.06%
Market Cap $883.2M
P/E Ratio 16.41x
Div. Yield -
ROE 19.40%
Bulios Fair Price
$19.95
17.2% upside
Current Price
$17.02
Undervalued Fair Value Overvalued
According to Bulios Fair Price, TBPH is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
66 /100
Fair P/E 16.41x
EV/EBITDA 10.25x
P/S 8.47x
Growth
78 /100
Growing Rev. growth 27.91%
Book val. growth 12.43%
EPS growth N/A
Profitability
76 /100
Strong Gross margin 89.40%
Net margin 51.58%
Op. margin 4.46%
Quality
44 /100
Average ROIC 0.95%
ROE 19.40%
ROA 11.45%
Debt
100 /100
Low Debt/Equity 0.13x
Current ratio 13.54x
Int. coverage 55.59x
Stability
11 /100
Unstable Beta 0.17x
Rev. volatility 31.72%
EPS volatility 160.52%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about TBPH
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Rick E. Winningham
Employees
90
Headquarters
South San Francisco
Upcoming events
10 NOV
Earnings
Upcoming earnings report